• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 11, 2014

View Archived Issues

Next step on the path to 21st century cures: Draft legislation

A House subcommittee is getting ready to take the next step toward accelerating the development of new cures for the 21st century. Read More

LatAm seeks innovation resulting in 'extraordinary opportunity' to collaborat

RIO DE JANEIRO – The first-ever BIO Latin America conference opened Wednesday morning, with roughly 450 registered attendees to talk about the biotech sector, with much of the focus on fostering innovation and collaboration. Read More

Strategic incentivizing is a likely bet, but when will the payoffs start?

RIO DE JANEIRO – Brazil's investments in science and technology have increased by more than 550 percent over the last decade, thanks in large part to a series of innovative programs to reward entrepreneurs and leverage the best research. Read More

AM Pharma brings in $15.8M for phase II of acute kidney injury drug

LONDON – AM Pharma BV has raised €12.2 million (US$15.8 million) to fund a phase II 290-patient study of its human recombinant alkaline phosphatase product Recap, in what it said will be the largest-ever trial in acute kidney injury. Read More

Mylan strikes $300M deal to buy Arixtra rights, generic

A Mylan Inc. subsidiary will pay up to $300 million to acquire U.S. commercialization, marketing and IP rights for the anticoagulant Arixtra (fondaparinux) and an authorized generic (AG) of the drug from Aspen Global Inc. in a deal it said will be immediately accretive to adjusted earnings. Read More

Aslan's gastric cancer candidate enters the clinic in Taiwan

TAIPEI, Taiwan – Oncology-focused Aslan Pharmaceuticals Pte. Ltd. has started dosing the first patients in a safety study of its lead compound ASLAN001, a small-molecule, oral pan-HER inhibitor for the treatment of solid tumors. Read More

EMDAC to consider BLA for Natpara to treat hypoparathyroidism

Ahead of Friday's FDA Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting, briefing materials have been posted related to the biologic license application (BLA) for Natpara (rhPTH[1-84]) developed by NPS Pharmaceuticals Inc., of Bedminster, N.J. Read More

Financings

Airway Therapeutics LLC, of Cincinnati, said it secured $4.6 million in a series A financing round with Cincytech leading the round and participation from the Cincinnati Children's Hospital Medical Center, Queen City Angels and private investors. Read More

Other news to note

Cempra Inc., of Chapel Hill, N.C., said it received a $10 million milestone payment from Toyama Chemical Co., a subsidiary of Fujifilm Holdings Corp., triggered by the progress of its solithromycin, which obtained regulatory clearance to begin a phase II trial in Japan. Read More

In the clinic

G1 Therapeutics Inc., of Research Triangle Park, N.C., said it initiated a phase I trial of G1T28-1, a CDK4/6 inhibitor with broad potential in multiple oncology indications. Read More

Pharma: Other news to note

Eli Lilly and Co., of Indianapolis, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, received marketing authorization for insulin glargine to treat diabetes in the EU, making it the first insulin approved through the biosimilar pathway there. Read More

Stock movers

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe